메뉴 건너뛰기




Volumn 13, Issue 6, 2011, Pages

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

Author keywords

Adjuvant docetaxel; Breast cancer; Ki67; Molecular subtypes

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

EID: 80055061495     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3051     Document Type: Article
Times cited : (22)

References (58)
  • 1
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials
    • Early Breast Cancer Trialists' Collaborative Group
    • Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 2
    • 74849135474 scopus 로고    scopus 로고
    • Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization
    • 10.1007/s10549-009-0433-y, 19526354
    • Sparano JA, Hortobagyi GN, Gralow JR, Perez EA, Comis RL. Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Res Treat 2010, 119:511-527. 10.1007/s10549-009-0433-y, 19526354.
    • (2010) Breast Cancer Res Treat , vol.119 , pp. 511-527
    • Sparano, J.A.1    Hortobagyi, G.N.2    Gralow, J.R.3    Perez, E.A.4    Comis, R.L.5
  • 3
    • 76849087811 scopus 로고    scopus 로고
    • Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
    • 10.1038/nrclinonc.2009.186, 19997076
    • Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010, 7:22-36. 10.1038/nrclinonc.2009.186, 19997076.
    • (2010) Nat Rev Clin Oncol , vol.7 , pp. 22-36
    • Bedard, P.L.1    Di Leo, A.2    Piccart-Gebhart, M.J.3
  • 6
    • 20544434991 scopus 로고    scopus 로고
    • Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28
    • 10.1200/JCO.2005.10.517, 15897552
    • Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696. 10.1200/JCO.2005.10.517, 15897552.
    • (2005) J Clin Oncol , vol.23 , pp. 3686-3696
    • Mamounas, E.P.1    Bryant, J.2    Lembersky, B.3    Fehrenbacher, L.4    Sedlacek, S.M.5    Fisher, B.6    Wickerham, D.L.7    Yothers, G.8    Soran, A.9    Wolmark, N.10
  • 11
    • 73949090093 scopus 로고    scopus 로고
    • Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer
    • 2799234, 19901117
    • Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O''Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 2009, 28:77-82. 2799234, 19901117.
    • (2009) J Clin Oncol , vol.28 , pp. 77-82
    • Burnell, M.1    Levine, M.N.2    Chapman, J.A.3    Bramwell, V.4    Gelmon, K.5    Walley, B.6    Vandenberg, T.7    Chalchal, H.8    Albain, K.S.9    Perez, E.A.10    Rugo, H.11    Pritchard, K.12    O'Brien, P.13    Shepherd, L.E.14
  • 17
    • 51749093141 scopus 로고    scopus 로고
    • Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    • 10.1200/JCO.2008.16.7841, 2654376, 18678836
    • Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008, 26:4092-4099. 10.1200/JCO.2008.16.7841, 2654376, 18678836.
    • (2008) J Clin Oncol , vol.26 , pp. 4092-4099
    • Goldstein, L.J.1    O'Neill, A.2    Sparano, J.A.3    Perez, E.A.4    Shulman, L.N.5    Martino, S.6    Davidson, N.E.7
  • 21
    • 76849117354 scopus 로고    scopus 로고
    • Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group
    • Intergruppo GONO-M
    • Del Mastro L, Costantini M, Durando A, Michelotti A, Danese S, Aitini E, Olmeo N, Pronzato P, Venturini M, . Intergruppo GONO-M Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group. J Clin Oncol 2008, 26:a516. Intergruppo GONO-M.
    • (2008) J Clin Oncol , vol.26
    • Del Mastro, L.1    Costantini, M.2    Durando, A.3    Michelotti, A.4    Danese, S.5    Aitini, E.6    Olmeo, N.7    Pronzato, P.8    Venturini, M.9
  • 22
    • 76849098541 scopus 로고    scopus 로고
    • Interim results of Intergroup EC-Doc Trial: a randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1-3 positive lymph nodes [abstract]
    • West German Study Group/AGO-Mamma
    • Nitz U, Huober JB, Lisboa B, Harbeck N, Fischer H, Moebus V, Hoffmann G, Augustin D, Weiss E, Kuhn W, . West German Study Group/AGO-Mamma Interim results of Intergroup EC-Doc Trial: a randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1-3 positive lymph nodes [abstract]. J Clin Oncol 2008, 26:a515. West German Study Group/AGO-Mamma.
    • (2008) J Clin Oncol , vol.26
    • Nitz, U.1    Huober, J.B.2    Lisboa, B.3    Harbeck, N.4    Fischer, H.5    Moebus, V.6    Hoffmann, G.7    Augustin, D.8    Weiss, E.9    Kuhn, W.10
  • 27
    • 45749149210 scopus 로고    scopus 로고
    • Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis
    • 10.1200/JCO.2007.14.9146, 18509176
    • Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 2008, 26:2636-2643. 10.1200/JCO.2007.14.9146, 18509176.
    • (2008) J Clin Oncol , vol.26 , pp. 2636-2643
    • Andre, F.1    Broglio, K.2    Roche, H.3    Martin, M.4    Mackey, J.R.5    Penault-Llorca, F.6    Hortobagyi, G.N.7    Pusztai, L.8
  • 32
    • 77955097761 scopus 로고    scopus 로고
    • BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy
    • 10.1158/1078-0432.CCR-10-0079, 20576719
    • Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechere L, Reed JC. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 2010, 16:3988-3997. 10.1158/1078-0432.CCR-10-0079, 20576719.
    • (2010) Clin Cancer Res , vol.16 , pp. 3988-3997
    • Dumontet, C.1    Krajewska, M.2    Treilleux, I.3    Mackey, J.R.4    Martin, M.5    Rupin, M.6    Lafanechere, L.7    Reed, J.C.8
  • 36
    • 48849096940 scopus 로고    scopus 로고
    • Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients
    • 10.1016/j.breast.2008.02.002, 18455396
    • Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17:323-334. 10.1016/j.breast.2008.02.002, 18455396.
    • (2008) Breast , vol.17 , pp. 323-334
    • Stuart-Harris, R.1    Caldas, C.2    Pinder, S.E.3    Pharoah, P.4
  • 39
    • 0037314676 scopus 로고    scopus 로고
    • Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study
    • Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003, 9:686-692.
    • (2003) Clin Cancer Res , vol.9 , pp. 686-692
    • Estevez, L.G.1    Cuevas, J.M.2    Anton, A.3    Florian, J.4    Lopez-Vega, J.M.5    Velasco, A.6    Lobo, F.7    Herrero, A.8    Fortes, J.9
  • 44
    • 20544434991 scopus 로고    scopus 로고
    • Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28
    • 10.1200/JCO.2005.10.517, 15897552
    • Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696. 10.1200/JCO.2005.10.517, 15897552.
    • (2005) J Clin Oncol , vol.23 , pp. 3686-3696
    • Mamounas, E.P.1    Bryant, J.2    Lembersky, B.3    Fehrenbacher, L.4    Sedlacek, S.M.5    Fisher, B.6    Wickerham, D.L.7    Yothers, G.8    Soran, A.9    Wolmark, N.10
  • 47
    • 71749084050 scopus 로고    scopus 로고
    • Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?
    • Hayes DF. Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?. Breast 2009, 18:S131-134.
    • (2009) Breast , vol.18
    • Hayes, D.F.1
  • 48
    • 34247508923 scopus 로고    scopus 로고
    • Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
    • 10.1158/1078-0432.CCR-06-2078, 17404087
    • Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007, 13:2061-2067. 10.1158/1078-0432.CCR-06-2078, 17404087.
    • (2007) Clin Cancer Res , vol.13 , pp. 2061-2067
    • Andre, F.1    Hatzis, C.2    Anderson, K.3    Sotiriou, C.4    Mazouni, C.5    Mejia, J.6    Wang, B.7    Hortobagyi, G.N.8    Symmans, W.F.9    Pusztai, L.10
  • 49
    • 33746604292 scopus 로고    scopus 로고
    • Predictive factors for response to docetaxel in human breast cancers
    • 10.1111/j.1349-7006.2006.00265.x, 16805818
    • Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006, 97:813-820. 10.1111/j.1349-7006.2006.00265.x, 16805818.
    • (2006) Cancer Sci , vol.97 , pp. 813-820
    • Noguchi, S.1
  • 50
    • 0029956081 scopus 로고    scopus 로고
    • Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
    • 10.1038/nm0796-811, 8673929
    • Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2:811-814. 10.1038/nm0796-811, 8673929.
    • (1996) Nat Med , vol.2 , pp. 811-814
    • Aas, T.1    Borresen, A.L.2    Geisler, S.3    Smith-Sorensen, B.4    Johnsen, H.5    Varhaug, J.E.6    Akslen, L.A.7    Lonning, P.E.8
  • 51
    • 0030026934 scopus 로고    scopus 로고
    • Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
    • 10.1038/nm0196-72, 8564846
    • Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2:72-79. 10.1038/nm0196-72, 8564846.
    • (1996) Nat Med , vol.2 , pp. 72-79
    • Wahl, A.F.1    Donaldson, K.L.2    Fairchild, C.3    Lee, F.Y.4    Foster, S.A.5    Demers, G.W.6    Galloway, D.A.7
  • 52
    • 77951925779 scopus 로고    scopus 로고
    • Gene expression profiling of breast cancer
    • Pusztai L. Gene expression profiling of breast cancer. Breast Cancer Res 2009, 11:S11.
    • (2009) Breast Cancer Res , vol.11
    • Pusztai, L.1
  • 53
    • 79960980007 scopus 로고    scopus 로고
    • Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    • 10.1093/annonc/mdr304, 3144634, 21709140
    • Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747. 10.1093/annonc/mdr304, 3144634, 21709140.
    • (2011) Ann Oncol , vol.22 , pp. 1736-1747
    • Goldhirsch, A.1    Wood, W.C.2    Coates, A.S.3    Gelber, R.D.4    Thurlimann, B.5    Senn, H.J.6
  • 55
    • 27244443082 scopus 로고    scopus 로고
    • Proliferation marker Ki-67 in early breast cancer
    • 10.1200/JCO.2005.07.501, 16192605
    • Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23:7212-7220. 10.1200/JCO.2005.07.501, 16192605.
    • (2005) J Clin Oncol , vol.23 , pp. 7212-7220
    • Urruticoechea, A.1    Smith, I.E.2    Dowsett, M.3
  • 57
    • 75249083420 scopus 로고    scopus 로고
    • Ki67 in breast cancer: prognostic and predictive potential
    • 10.1016/S1470-2045(09)70262-1, 20152769
    • Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11:174-183. 10.1016/S1470-2045(09)70262-1, 20152769.
    • (2010) Lancet Oncol , vol.11 , pp. 174-183
    • Yerushalmi, R.1    Woods, R.2    Ravdin, P.M.3    Hayes, M.M.4    Gelmon, K.A.5
  • 58
    • 0034668136 scopus 로고    scopus 로고
    • A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data
    • 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M, 10986536
    • Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000, 19:2595-2609. 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M, 10986536.
    • (2000) Stat Med , vol.19 , pp. 2595-2609
    • Bonetti, M.1    Gelber, R.D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.